Deal typePrivate Equity & Transaction Services
IndustryLife Sciences
Client nameEvestia Clinical
BDO has provided financial due diligence to Evestia Clinical, a leading independent global specialist Contract Research Organization (CRO), on their acquisition of ICRC-Weyer, a Berlin-based, long-established CRO and scientific consultancy. The work was delivered by a combined team from BDO UK and BDO Germany.
The acquisition strengthens Evestia Clinical's presence in Germany and Europe and further enhances the Company's full-service clinical research solutions for biotech innovators.
ICRC-Weyer brings a strong heritage in data-driven clinical research, with deep scientific and operational expertise in biostatistics, data management, and medical writing across the full clinical development cycle. Integrating these specialist capabilities expands Evestia Clinical's European presence and gives biotech innovators enhanced access to high-quality services that are increasingly critical as clinical trial development grows in complexity and regulatory expectations evolve. At the same time, ICRC-Weyer’s clients will benefit from access to Evestia Clinical’s full suite of global clinical trial services from Phase I-III and beyond, providing more integrated, end-to-end support across core therapeutic areas including oncology, neurology, and rare diseases.
The BDO project team included:
Graeme Hurst, Lewis Winston (BDO UK Financial due diligence)
Martin Studier, Nassim Saleh, Ole de Vries (BDO Germany Financial due diligence)
The acquisition strengthens Evestia Clinical's presence in Germany and Europe and further enhances the Company's full-service clinical research solutions for biotech innovators.
ICRC-Weyer brings a strong heritage in data-driven clinical research, with deep scientific and operational expertise in biostatistics, data management, and medical writing across the full clinical development cycle. Integrating these specialist capabilities expands Evestia Clinical's European presence and gives biotech innovators enhanced access to high-quality services that are increasingly critical as clinical trial development grows in complexity and regulatory expectations evolve. At the same time, ICRC-Weyer’s clients will benefit from access to Evestia Clinical’s full suite of global clinical trial services from Phase I-III and beyond, providing more integrated, end-to-end support across core therapeutic areas including oncology, neurology, and rare diseases.
"It was great to continue our support of Evestia Clinical by providing financial due diligence support on their acquisition of ICRC-Weyer. This was a great opportunity to demonstrate our collaborative international approach at BDO, utilising our local German experts, enhanced with the strong Life Science and Healthcare sector team in the UK."
Lewis Winston, Director, BDO LLP
The BDO project team included:
Graeme Hurst, Lewis Winston (BDO UK Financial due diligence)
Martin Studier, Nassim Saleh, Ole de Vries (BDO Germany Financial due diligence)